Cargando…

A novel concentrated growth factor (CGF) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study

BACKGROUND: The extraction of impacted mandibular third molars might cause large bone defects in the distal area of second molars. A new strategy was innovatively employed here combining autologous bone, Bio-Oss, concentrated growth factors (CGF) gel and CGF membrane for bone repair, and the present...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Shoufu, Xu, Xiaodong, Zhang, Zhongxiao, Zhang, Ying, Wei, Wenjia, Guo, Ke, Jiang, Yunan N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571244/
https://www.ncbi.nlm.nih.gov/pubmed/37828455
http://dx.doi.org/10.1186/s12903-023-03411-2
_version_ 1785119944995766272
author Sun, Shoufu
Xu, Xiaodong
Zhang, Zhongxiao
Zhang, Ying
Wei, Wenjia
Guo, Ke
Jiang, Yunan N.
author_facet Sun, Shoufu
Xu, Xiaodong
Zhang, Zhongxiao
Zhang, Ying
Wei, Wenjia
Guo, Ke
Jiang, Yunan N.
author_sort Sun, Shoufu
collection PubMed
description BACKGROUND: The extraction of impacted mandibular third molars might cause large bone defects in the distal area of second molars. A new strategy was innovatively employed here combining autologous bone, Bio-Oss, concentrated growth factors (CGF) gel and CGF membrane for bone repair, and the present study aimed at exploring safety as well as short- and long-term efficacy of this new protocol clinically. MATERIALS AND METHODS: A total of 66 participants were enrolled in this randomized single-blind clinical trial, and randomly allocated to control group (only blood clots), test A group (autogenous bone, Bio-Oss with barrier membrane) and test B group (autogenous bone, Bio-Oss, CGF gel with CGF membrane). The postoperative outcomes including PoSSe scale, periodontal probing depth (PD), degree of gingival recession and computed tomography measurements were assessed at 3rd, 6th, 12th month. A p-value < 0.05 was considered statistically significant. RESULTS: In PoSSe scale, no significant difference was observed except a significant alleviation of early-stage pain perception in test B group (p < 0.05). Also, test B group exhibited better effect on periodontal healing and gingival recession reduction after 6 months (p < 0.05). Both two test groups showed more new bone formation than the control group (p < 0.05). It is noteworthy that the bone repair of test B group was significantly better than that of test A at 3rd and 6th month (p < 0.05), yet no difference was observed at 12th month (p > 0.05). CONCLUSION: Both two test groups could achieve stable long-term efficacy on bone defect repair. The use of CGF gel and CGF membrane could accelerate early-stage bone repair, alleviate short-term pain after surgery, reduce long-term probing depth and relieve economic cost for patients. This new bone repair protocol is worthy of promoting by clinicians. TRIAL REGISTRATION: This study was registered with the identification number ChiCTR2300068466 on 20/02/2023 at Chinese Clinical Trial Registry. Also, it was ethically approved from the institutional ethics committee at the Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (No:2023-010-01), and has been conducted in accordance to the guidelines of the declaration of Helsinki. Written informed consent was obtained from all participants in the study. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12903-023-03411-2.
format Online
Article
Text
id pubmed-10571244
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105712442023-10-14 A novel concentrated growth factor (CGF) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study Sun, Shoufu Xu, Xiaodong Zhang, Zhongxiao Zhang, Ying Wei, Wenjia Guo, Ke Jiang, Yunan N. BMC Oral Health Research BACKGROUND: The extraction of impacted mandibular third molars might cause large bone defects in the distal area of second molars. A new strategy was innovatively employed here combining autologous bone, Bio-Oss, concentrated growth factors (CGF) gel and CGF membrane for bone repair, and the present study aimed at exploring safety as well as short- and long-term efficacy of this new protocol clinically. MATERIALS AND METHODS: A total of 66 participants were enrolled in this randomized single-blind clinical trial, and randomly allocated to control group (only blood clots), test A group (autogenous bone, Bio-Oss with barrier membrane) and test B group (autogenous bone, Bio-Oss, CGF gel with CGF membrane). The postoperative outcomes including PoSSe scale, periodontal probing depth (PD), degree of gingival recession and computed tomography measurements were assessed at 3rd, 6th, 12th month. A p-value < 0.05 was considered statistically significant. RESULTS: In PoSSe scale, no significant difference was observed except a significant alleviation of early-stage pain perception in test B group (p < 0.05). Also, test B group exhibited better effect on periodontal healing and gingival recession reduction after 6 months (p < 0.05). Both two test groups showed more new bone formation than the control group (p < 0.05). It is noteworthy that the bone repair of test B group was significantly better than that of test A at 3rd and 6th month (p < 0.05), yet no difference was observed at 12th month (p > 0.05). CONCLUSION: Both two test groups could achieve stable long-term efficacy on bone defect repair. The use of CGF gel and CGF membrane could accelerate early-stage bone repair, alleviate short-term pain after surgery, reduce long-term probing depth and relieve economic cost for patients. This new bone repair protocol is worthy of promoting by clinicians. TRIAL REGISTRATION: This study was registered with the identification number ChiCTR2300068466 on 20/02/2023 at Chinese Clinical Trial Registry. Also, it was ethically approved from the institutional ethics committee at the Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (No:2023-010-01), and has been conducted in accordance to the guidelines of the declaration of Helsinki. Written informed consent was obtained from all participants in the study. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12903-023-03411-2. BioMed Central 2023-10-12 /pmc/articles/PMC10571244/ /pubmed/37828455 http://dx.doi.org/10.1186/s12903-023-03411-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sun, Shoufu
Xu, Xiaodong
Zhang, Zhongxiao
Zhang, Ying
Wei, Wenjia
Guo, Ke
Jiang, Yunan N.
A novel concentrated growth factor (CGF) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study
title A novel concentrated growth factor (CGF) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study
title_full A novel concentrated growth factor (CGF) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study
title_fullStr A novel concentrated growth factor (CGF) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study
title_full_unstemmed A novel concentrated growth factor (CGF) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study
title_short A novel concentrated growth factor (CGF) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study
title_sort novel concentrated growth factor (cgf) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571244/
https://www.ncbi.nlm.nih.gov/pubmed/37828455
http://dx.doi.org/10.1186/s12903-023-03411-2
work_keys_str_mv AT sunshoufu anovelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy
AT xuxiaodong anovelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy
AT zhangzhongxiao anovelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy
AT zhangying anovelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy
AT weiwenjia anovelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy
AT guoke anovelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy
AT jiangyunann anovelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy
AT sunshoufu novelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy
AT xuxiaodong novelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy
AT zhangzhongxiao novelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy
AT zhangying novelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy
AT weiwenjia novelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy
AT guoke novelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy
AT jiangyunann novelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy